

Publication List:

1. Bronner C, Alhosin M, Hamiche A, **Mousli M**. Coordinated Dialogue between UHRF1 and DNMT1 to Ensure Faithful Inheritance of Methylated DNA Patterns. *Genes*. 18:10. **2019**
2. Ashraf W, Bronner C, Zaayter L, Ahmad T, Richert L, Alhosin M, Ibrahim A, Hamiche A, Mely Y, **Mousli M**. Interaction of the epigenetic integrator UHRF1 with the MYST domain of TIP60 inside the cell. *J Exp Clin Cancer Res*. doi: 10.1186/s13046-017-0659-1. 36:188. **2017**
3. Ashraf W, Ibrahim A, Alhosin M, Zaayter L, Ouararhni K, Papin C, Ahmad T, Hamiche A, Mély Y, Bronner C, **Mousli M**. The epigenetic integrator UHRF1: on the road to become a universal biomarker for cancer. *Oncotarget*. doi: 10.18632/oncotarget.17393. **2017**
4. Kilin V, Gavvala K, Barthes NP, Michel BY, Shin D, Boudier C, Mauffret O, Yashchuk V, **Mousli M**, Ruff M, Granger F, Eiler S, Bronner C, Tor Y, Burger A, Mély Y. Dynamics of Methylated Cytosine Flipping by UHRF1. *J Am Chem Soc*. 139: 2520-2528. **2017**
5. Alhosin M, Omran Z, Zamzami MA, Al-Malki AL, Choudhry H, **Mousli M**, Bronner C. Signalling pathways in UHRF1-dependent regulation of tumor suppressor genes in cancer. *J Exp Clin Cancer Res*. 35:174. **2016**
6. Boukhari A, Alhosin M, Bronner C, Sagini K, Truchot C, Sick E, Schini-Kerth VB, André P, Mély Y, **Mousli M**, Gies JP. CD47 Activation-induced UHRF1 Over-expression Is Associated with Silencing of Tumor Suppressor Gene p16INK4A in Glioblastoma Cells. *Anticancer Res*. 35:149-57. **2015**
7. Krifa M, Leloup L, Ghedira K, **Mousli M**, Chekir-Ghedira L. Luteolin induces apoptosis in BE colorectal cancer cells by downregulating calpain, UHRF1, and DNMT1 expressions. *Nutr. Cancer*. 66:1220-1227. **2014**
8. Krifa M, Pizzi A, **Mousli M**, Chekir-Ghedira L, Leloup L, Ghedira K. Limoniastrum guyonianum aqueous gall extract induces apoptosis in colorectal cancer cells by inhibiting calpain activity. *Tumour Biol*. 35:7877-85. **2014**
9. Bronner C, Krifa M, **Mousli M**. Increasing role of UHRF1 in the reading and inheritance of the epigenetic code as well as in tumorigenesis. *Biochem Pharmacol*. 86:1643-9. **2013**
10. Krifa M, Alhosin M, Muller CD, Gies JP, Chekir-Ghedira L, Ghedira K, Mély Y, Bronner C, **Mousli M**. Limoniastrum guyonianum aqueous gall extract induces apoptosis in human cervical cancer cells

- involving p16 INK4A re-expression related to UHRF1 and DNMT1 down-regulation. **J Exp Clin Cancer Res.** 20:32-30. **2013**
11. Achour M, **Mousli M**, Alhosin M, Ibrahim A, Peluso J, Muller CD, Schini-Kerth VB, Hamiche A, Dhe-Paganon S, Bronner C. Epigallocatechin-3-gallate up-regulates tumor suppressor gene expression via a reactive oxygen species-dependent down-regulation of UHRF1. **Biochem Biophys Res Commun.** 430:208-12. **2013**
 12. Alhosin M, Sharif T, **Mousli M**, Etienne-Selloum N, Fuhrmann G, Schini-Kerth VB, Bronner C. Down-regulation of UHRF1, associated with re-expression of tumor suppressor genes, is a common feature of natural compounds exhibiting anti-cancer properties. **J Exp Clin Cancer Res.** 15: 30-41. **2011**
 13. Lahmar I, Guinard M, Sauer A, Marcellin L, Abdelrahman T, Roux M, **Mousli M**, Moussa A, Babba H, Pfaff AW, Candolfi E. Murine neonatal infection provides an efficient model for congenital ocular toxoplasmosis. **Exp Parasitol.** 124:190-6. **2010**
 14. Akaddar A, Doderer-Lang C, Marzahn MR, Delalande F, **Mousli M**, Helle K, Van Dorsselaer A, Aunis D, Dunn BM, Metz-Boutigue MH, Candolfi E. Catestatin, an endogenous chromogranin A-derived peptide, inhibits in vitro growth of Plasmodium falciparum. **Cell Mol Life Sci.** 67:1005-15. **2010**
 15. Achour M, Fuhrmann G, Alhosin M, Rondé P, Chataigneau T, **Mousli M**, Schini-Kerth VB, Bronner C. UHRF1 recruits the histone acetyltransferase Tip60 and controls its expression and activity. **Biochem Biophys Res Commun.** 390:523-8 **2009**
 16. Unoki M, Brunet J, **Mousli M**. Drug discovery targeting epigenetic codes: the great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis. **Biochem. Pharmacol.** 78:1279-88. **2009**
 17. Lahmar I, Abou-Bacar A, Abdelrahman T, Guinard M, Babba H, Ben Yahia S, Kairallah M, Speeg-Schatz C, Bourcier T, Sauer A, Villard O, Pfaff AW, **Mousli M**, Garweg JG, Candolfi E. Cytokine profiles in toxoplasmic and viral uveitis. **J. Infect. Dis.** 199:1239-49. **2009**
 18. Senegas A, Villard O, Neuville A, Marcellin L, Pfaff AW, Steinmetz T, **Mousli M**, Klein JP, Candolfi E. Toxoplasma gondii-induced foetal resorption in mice involves interferon-gamma-induced apoptosis and spiral artery dilation at the maternofetal interface. **Int J Parasitol.**, 39:481-7. **2009**

19. J. Brunet, A.W. Pfaff, A. Abidi, M. Unoki, Y. Nakamura, M. Guinard, J.P. Klein, E. Candolfi, **M. Mousli**. *Toxoplasma gondii* exploits UHRF1 and induces host cell cycle arrest at G2 to enable its proliferation. **Cell Microbiol.** 10, 908-920. **2008**
20. M. Unoki , C. Bronner, **M. Mousli**. A Concern Regarding the Current Confusion with the Human Homolog of Mouse Np95, ICBP90/UHRF1. **Radiat. Res.** 169, 240-4, **2008**
21. A.W. Pfaff, **M. Mousli**, A. S negas, L. Marcellin, O. Takikaw, J.P. Klein, E. Candolf. Impact of foetus and mother on IFN-gamma-induced indoleamine 2,3-dioxygenase and inducible nitric oxide synthase expression in murine placenta following *Toxoplasma gondii* infection. **Int J Parasitol.** 38, 249-58. **2008**
22. A.W. Pfaff, A. Abou-Bacar, V. Letscher-Br, O. Villard, A. Senegas, **M. Mousli**, E. Candolf. Cellular and molecular physiopathology of congenital toxoplasmosis: the dual role of IFN-gamma. **Parasitology.** 134, 1895-902. **2007**.
23. R. Rajapakse, **M. Mousli**, A.W. Pfaff, B. Uring-Lambert, L. Marcellin, C. Bronner, M. Jeanblanc, O. Villard, V. Letscher-Bru, J.P. Klein and E. Candolfi: 1,25-dihydroxyvitamin D3 induces splenocyte apoptosis and enhances BALB/c mice sensitivity to toxoplasmosis. **J. Steroid Biochem. Mol. Biol.**, 96, 179-185. **2005**.
24. A.Q. Abbady, C. Bronner, K. Bathami, C.D. Muller, M. Jeanblanc, E. Mathieu, J.P. Klein, E. Candolfi and **M. Mousli**. TCR pathway involves ICBP90 gene down-regulation via E2F binding sites. **Biochem. Pharmacol.**, 70, 570-579. **2005**.
25. M. Jeanblanc, **M. Mousli**, R. Hopfner, K. Bathami, N. Martinet, A.Q. Abbady, J.C. Siffert, E. Mathieu, C.D. Muller and C. Bronner. The retinoblastoma gene and its product are targeted by ICBP90: a key mechanism in the G1/S transition during the cell cycle. **Oncogene**, 24,7337-7345. **2005**
26. A.W. Pfaff, S. Georges, A. Abou-Bacar, V. Letscher-Bru, J.P. Klein, **M. Mousli**, and E. Candolfi. *Toxoplasma gondii* regulates ICAM-1 mediated monocyte adhesion to trophoblasts. **Immunol. Cell Biol.**, 83, 483-489. **2005**.
27. A.W. Pfaff, O. Villard, J.P. Klein, **M. Mousli** and E. Candolfi. Regulation of *Toxoplasma gondii* multiplication in BeWo trophoblast cells: cross-regulation of nitric oxide production and polyamine biosynthesis. **Int. J. Parasitol.**, 35:1569-1576. **2005**.

28. Y. Arima, T. Hirota, C. Bronner, **M. Mousli**, T. Fujiwara, S. Niwa, H. Ishikawa and H. Saya. Downregulation of nuclear protein ICBP90 by p53/p21^{Cip1/WAF1}-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition, **Genes Cells**, 9, 131-142. **2004**.
29. M. Jeanblanc, **M. Mousli** K. Bathami K., E. Mathieu E., A.Q. Abbady and C. Bronner. Effet suppresseur du facteur de transcription ICBP90 sur l'activité et l'expression de la protéine régulatrice pRB : implication dans le contrôle de la transition G1/S du cycle cellulaire. **B. Cancer**, 91: 497. **2004**
30. M.A. Trotzier, C. Bronner, K. Bathami, E. Mathieu, A.Q. Abbady, M. Jeanblanc, C.D. Muller, C. Rochette-Egly and **M. Mousli**. Phosphorylation of ICBP90 by protein kinase A enhances topoisomerase II α expression, **Biochem. Biophys. Res. Comm.**, 319, 590-595. **2004**.
31. C. Bronner, M.A. Trotzier, O. Filho, C. Cochet, C. Rochette-Egly, M. Scholler-Guinard, J.P. Klein, **M. Mousli**. The Antiapoptotic Protein ICBP90 Is a Target for Protein Kinase II, **Ann. NY Acad. Sci.**, 1030, 355-360. **2004**.
32. **M. Mousli**, R. Hopfner, A. Abbady, D. Monté, M. Jeanblanc, P. Oudet, B. Louis, C. Bronner. ICBP90 belongs to a new family of proteins with an expression that is deregulated in cancer cells, **Br. J. Cancer**, 89, 120-127. **2003**.
33. A.Q. Abbady, C. Bronner, M.A. Trotzier, R. Hopfner, K. Bathami, C.D. Muller, M. Jeanblanc and **M. Mousli**, ICBP90 expression is down-regulated in apoptosis-induced Jurkat cells, **Ann. NY Acad. Sci.**, 1010, 300-303. **2003**.
34. R. Hopfner, **M. Mousli**, P. Oudet, C. Bronner. Overexpression of ICBP90, a novel CCAAT-binding protein, overcomes cell contact inhibition by forcing topoisomerase II alpha expression, **Anticancer Res.** 22, 3165-3170. **2002**.
35. R. Hopfner, **M. Mousli**, J. M. Garnier, R. Redon, S. duManoir, B. Chatton, N. Ghyselinck, P. Oudet and C. Bronner. Genomic structure and chromosomal mapping of the gene coding for ICBP90, a protein involved in the regulation of topoisomerase II α gene expression. **Gene**, 266, 15-23, **2001**.
36. C. Bronner, R. Hopfner and **M. Mousli**. Regulation of the human topoisomerase II α gene expression: is ICBP90 one of the missing piece of the puzzle? **Anticancer Res.**, 21, 1542, **2001**.
37. C. Bronner, R. Hopfner and **M. Mousli**. Regulation of the human topoisomerase II α gene expression by ICBP90, a universal marker for cancer cells. **Int. J. Mol. Med.**, 8, S88. **2001**.

38. **M. Mousli**, R. Hopfner, K. Bathami, C. Marin, J.P. Bellocq, J.M. Vignaud, B. Louis and C. Bronner. ICBP90 (Inverted CCAAT box Binding Protein of 90 kDa): un nouveau marqueur de prolifération des cellules cancéreuses. **B. Cancer**, 88, 508. **2001**.
39. R. Hopfner, **M. Mousli**, J.M. Jeltsch, A. Voulgaris, Y. Lutz, C. Marin, J.P. Bellocq, P. Oudet and C. Bronner. ICBP90, a novel CCAAT binding protein, involved in the regulation of topoisomerase II α expression. **Cancer Res.**, 60, 121-128, **2000**.
40. L. Brino, A. Urzhumtsev, **M. Mousli**, C. Bronner, A. Mitschler, P. Oudet and D. Moras. Dimerization of *Escherichia coli* DNA-gyrase B provides a structural mechanism for activating the ATPase catalytic center. **J. Biol. Chem.**, 275, 9468-9475, **2000**.
41. L. Brino, C. Bronner, P. Oudet and **M. Mousli**. Isoleucine 10 is essential for DNA gyrase B function in *Escherichia coli*. **Biochimie**, 81, 973-980, **1999**.
42. A. Chahdi, **M. Mousli** and Y. Landry. Substance P-related inhibitors of mast cell exocytosis act on G-proteins or on the cell surface. **Eur J Pharmacol.**, 341, 329-35. **1998**.
43. L. Brino, **M. Mousli**, P. Oudet and E. Weiss. Expression in *Escherichia coli* of Y5 mutant and N-terminal domain-deleted DNA gyrase B proteins affects strongly plasmid maintenance. **Plasmid**, 38, 188-201, **1997**.
44. J.G. Van Gelderen, L. Daeffler, D. Scherrer, **M. Mousli**, Y. Landry, J.P. Gies. M2-muscarinic receptors: how does ligand binding affinity relate to intrinsic activity? **J. Recept. Signal Transduct. Res.**, 16, 135-148. **1996**.
45. L. De Vries, **M. Mousli**, A. Wurmser and M. G. Farquhar. GAIP, a protein that interacts with the trimeric G protein G α i3, is a member of a protein family with a highly conserved core domain. **Proc. Natl. Acad. Sci. USA**, 92, 11916-11920, **1995**.
46. B. Emadi-Khiav, **M. Mousli**, C. Bronner and Y. Landry. Human and rat cutaneous mast cells: involvement of a G protein in the response to peptidergic stimuli. **Eur. J. Pharmacol., (Molec. Pharmacol. Sec.)**, 272, 97-102, **1995**.
47. **M. Mousli**, A. Trifilieff, J.T. Pelton, J. P. Gies and Y. Landry. Structural requirements for neuropeptide Y in mast cell and G protein activation. **Eur. J. Pharmacol., (Molec. Pharmacol. Sec.)**, 289, 125-133, **1995**.
48. **M. Mousli**, T.E. Hugli, Y. Landry and C. Bronner. Peptidergic pathway in human skin and rat peritoneal mast cell activation. **Immunopharmacology**, 27, 1-11, **1994**.

49. A. Trifilieff, E. Lach, **M. Mousli**, E. B. Haddad, Y. Landry and J. P. Gies. Co-solubilization of bradykinin B2 receptors and angiotensin-converting enzyme from guinea pig lung membranes. **Biochim. Biophys. Acta**, 1191, 109-116, **1994**.
50. **M. Mousli** and Y. Landry. Role of positive charges of neuropeptide Y fragments in mast cell activation. **Agent. Action.**, 41, C41-C42, **1994**.
51. E. Lach, A. Trifilieff, **M. Mousli**, Y. Landry and J. P. Gies. Bradykinin-induced contraction of guinea pig lung *in vitro*. **NS. Arch. Pharmacol.** 350, 201-208. **1994**.
52. T. Fischer, C. Bronner, Y. Landry and **M. Mousli**. The mechanism of inhibition of alkylamines on the mast cell peptidergic pathway. **Biochim. Biophys. Acta**, 1176, 305-312, **1993**.
53. J.L. Bueb, **M. Mousli** Y. Landry and D. Regoli. Structure-activity studies of bradykinin analogues on rat peritoneal mast cell histamine release. **Peptides**, 14, 685-689, **1993**.
54. **M. Mousli** and Y. Landry. The activation of G proteins by membrane receptors and peptides. Putative role for amphipathic helices ? In "The amphipathic helix", **R.M. Epand ed., CRC Press INC**, 313-332, **1993**.
55. J. P. Gies, Y. Landry and **M. Mousli**. Receptor-independent activation of mast cells by bradykinin and related peptides. **Trends Neuro Sci.**, 16, 498-499, **1993**.
56. D. Hillaire-Buys, **M. Mousli**, Y. Landry, J. Bockaert, J.A. Fehrentz, J. Carrette and B. Rouot. Insulin releasing effects of mastoparan and amphiphilic substance P receptor antagonists on RINm5F insulinoma cells. **Mol. Cell. Biochem.**, 109, 133-138, **1992**.
57. **M. Mousli**, T. Fischer and Y. Landry. Role of phospholipase A₂ and pertussis toxin-sensitive G proteins in histamine secretion induced by substance P. **Agent Action**, 36, C305-C307, **1992**.
58. J. L. Bueb, A. Da Silva, **M. Mousli** and Y. Landry. Natural polyamines stimulate G-proteins. **Biochem. J.**, 282, 545-550, **1992**.
59. **M. Mousli**, T.E. Hugli, Y. Landry and C. Bronner. A mechanism of action for anaphylatoxin C3a stimulation of mast cells. **J. Immunol.**, 148, 2456-2461, **1992**.
60. Y. Chen, **M. Mousli**, S. Thoret, R. Michelot and Y. Landry. Synthesis of new substance P analogues releasing histamine from rat peritoneal mast cells. **Eur. J. Med. Chem.**, 27, 931-937, **1992**.
61. **M. Mousli**, J. L. Bueb, B. Rouot, Y. Landry and C. Bronner. G proteins as targets for non-immunologic histamine releasers. **Agent. Action.**, 33, 81-83, **1991**.

62. **M. Mousli**, C. Bronner, J. L. Bueb and Y. Landry. Evidence for the interaction of mast-cell-degranulating-peptide (MCD) with pertussis toxin-sensitive G proteins in mast cells. **Eur. J. Pharmacol., (Molec. Pharmacol. Sec.),** 207, 249-255, **1991**.
63. **M. Mousli**, C. Bronner, Y. Landry, J. Bockaert and B. Rouot. Direct activation of GTP-binding regulatory proteins (G proteins) by substance P and compound 48/80. **FEBS Lett.,** 259, 260-262, **1990**.
64. **M. Mousli**, J. P. Gies, C. Bertrand F. Pelen, C. Bronner and Y. Landry. The sensitivity of Zn²⁺ discriminates between typical and atypical mast cells. **Agent. Action.,** 30, 102-105, **1990**.
65. J. L. Bueb, **M. Mousli**, Y. Landry and C. Bronner. A *pertussis* toxin-sensitive G protein is required to induce histamine release from rat peritoneal mast cells by bradykinin. **Agent. Action.,** 30, 98-101, **1990**.
66. **M. Mousli**, C. Bronner, J. Bockaert, B. Rouot and Y Landry. Interaction of substance P, compound 48/80 and mastoparan with α subunit C-terminal of G proteins. **Immunol. Lett.,** 25, 355-358, **1990**.
67. **M. Mousli**, J. L. Bueb, C. Bronner, B. Rouot and Y. Landry. G proteins activation : a receptor-independent mode of action for amphiphilic neuropeptides and venom peptides. **Trends Pharmacol. Sci.,** 11, 358-362, **1990**.
68. Y. Landry, J. L. Bueb, **M. Mousli** and C. Bronner. Mastocytes cutanés et inflammation neurogène. **Rev. Eur. Dermat. MST,** 2, 79-84, **1990**.
69. Y. Landry, J. G. Bloch, **M. Mousli**, J. L. Bueb and C. Bronner. Neuropeptides et inflammation : mécanismes présumés de l'inflammation neurogène. **Path. Biol.,** 38, 53-56, **1990**.
70. **M. Mousli**, J. L. Bueb, B. Rouot, J. Bockaert, Y. Landry and C. Bronner. Direct activation of G proteins : the mechanism of action of peptides on mast cells. XIth International Congress of Pharmacology, Amsterdam, Netherlands, 1990. **Eur. J. Pharmacol.,** 183, 1546-1547, **1990**.
71. Y. Landry, **M. Mousli**, J.C. Bueb and B. Rouot. Les protéines G: Cibles pharmacologiques potentielles. *In* **Pharmacologie Moléculaire**, Medsi/McGraw Hill, Paris, **1990**.
72. J. L. Bueb, **M. Mousli**, C. Bronner, B. Rouot and Y. Landry. Activation of Gi-like proteins, a receptor-independent effect of kinins in mast cells. **Molec. Pharmacol.,** 38, 816-822, **1990**.
73. C. Bronner, **M. Mousli**, N. Eleno and Y. Landry. The resting plasma membrane potential of rat mast cells is set predominantly by the sodium pump. **FEBS Lett.,** 255, 401-404, **1989**.

74. **M. Mousli**, C. Bronner, J. L. Bueb, E. Tschirhart, J. P. Gies and Y. Landry. Activation of rat peritoneal mast cells by substance P and mastoparan. **J. Pharmacol. Exp. Ther.**, 250, 329-335, **1989**.
75. **M. Mousli**, J. P. Gies, C. Bertrand, C. Bronner, F. Pelen and Y. Landry. Effets des ions Zn^{2+} sur différents modèles in vitro d'anaphylaxie. **Rev. Fr. Allerg. Immunol. Clin.**, 29, 191-195, **1989**.
76. E. Popin, C. Bertrand, **M. Mousli**, G. Pauli and Y. Landry. Contrôle peptidergique et concept d'inflammation neurogène. **Rev. Pneumol. Clin.**, 45, 141-143, **1989**.